A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473420 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Renal Failure
Chronic Kidney Disease

Interventions

BIOLOGICAL: Epoetin Hospira
BIOLOGICAL: Epogen Amgen

Sponsor

Pfizer

Collaborators

[object Object]